Stem Cell Potency: Totipotent and Pluripotent Cells Revision Notes | A Level AQA Biology

1. Why Stem Cell Potency Matters

Every cell in your body contains the same DNA — the same complete instruction manual. Yet a neuron looks and behaves nothing like a red blood cell. The question that unlocks this entire topic is: if every cell has the same genes, why do cells end up so different?

The answer lies in which genes are switched on or off — and when. Stem cell potency describes how many different cell types a given stem cell can still become. Understanding potency is the foundation for understanding both development and the clinical promise of stem cell therapies.

2. Totipotent Cells: The Most Powerful Starting Point

Picture a fertilised egg — a single zygote. At this moment, that one cell has the potential to produce every single type of cell the organism will ever need: muscle, nerve, liver, skin, and even the placenta and other extraembryonic tissues that support the pregnancy. A cell with this complete developmental range is called a totipotent cell.

The critical AQA specification point here is the time restriction: totipotent cells occur only for a limited time in early mammalian embryos. Once the embryo develops beyond the early morula stage and cells begin to commit to particular lineages, totipotency is lost. No adult tissue retains truly totipotent cells.

This limited window has enormous practical implications. It means that harvesting totipotent cells from a human embryo requires working with embryos at a very early developmental stage — raising significant ethical questions that we will return to in the evaluation section.

3. Pluripotent Cells: Powerful but Not Unlimited

As the early embryo develops past the morula stage, it forms a structure called the blastocyst. Inside the blastocyst is a cluster of cells called the inner cell mass. These cells have lost the ability to form extraembryonic tissues, but they can still produce virtually every cell type in the body. These are pluripotent cells — and they are the source of embryonic stem cells (ESCs) used in research and therapy.

The phrase "can divide in unlimited numbers" is specification language — use it precisely in exam answers. Pluripotent cells are self-renewing: they can keep producing copies of themselves indefinitely while retaining the capacity to differentiate. This makes them enormously valuable for producing large quantities of specialised cells for therapeutic use.

4. How Totipotent Cells Become Specialised: Selective Gene Expression

Here is the mechanism that ties everything together. Every cell in the body contains the full genome — the complete set of DNA. But during development, totipotent cells do not translate all of their DNA. Instead, they translate only a part of their DNA, and which part gets expressed determines what type of cell they become. This is the AQA specification's core mechanistic point: during development, totipotent cells translate only part of their DNA, resulting in cell specialisation.

Think of the genome as a vast library of books. Every cell has access to every book, but a muscle cell only reads the chapters on contractile proteins, while a pancreatic beta cell reads the chapters on insulin synthesis. The books that are not read in a given cell type are effectively silenced — their genes are not transcribed into mRNA and therefore not translated into protein.

Gene expression is controlled at multiple levels: transcription factors bind to promoter regions to switch genes on or off, and epigenetic modifications such as DNA methylation and histone deacetylation can silence genes without altering the DNA sequence itself. The result is that cells with identical DNA develop radically different structures and functions.

Worked example: Tracing the Path from Totipotent Cell to Specialised Cell

Describe, in sequence, how a totipotent cell in an early embryo gives rise to a specialised liver cell, linking each stage to the concept of selective gene expression.

1. Zygote / early morula cell — totipotent; all genes present and potentially expressible. — At this stage, no genes have been permanently silenced. The cell retains the capacity to become any cell type.
2. Cells of the inner cell mass become pluripotent — extraembryonic genes are silenced. — Specific transcription factors and epigenetic changes switch off genes needed only for placental tissue. The cell is now pluripotent, not totipotent.
3. Signalling molecules trigger expression of endoderm-specific transcription factors; genes for other lineages (e.g. muscle, nerve) are progressively silenced. — The cell is now committed to becoming a gut-derived tissue. It translates only the subset of DNA relevant to endodermal development.
4. Liver-specific genes (e.g. those encoding albumin, clotting factors) are actively transcribed; all other lineage genes remain silenced. — The cell now translates only the part of its DNA relevant to liver function. This is cell specialisation via selective gene expression.
5. The DNA sequence is identical in every cell. Specialisation arises because different genes are expressed (transcribed and translated) in different cell types. — This is the AQA specification point: totipotent cells translate only part of their DNA, resulting in cell specialisation. Examiners award marks for this precise causal link.

Answer: Totipotent cells contain the full genome. As development proceeds, selective gene expression — controlled by transcription factors and epigenetic modifications — progressively silences genes not needed for a given cell type. The cell translates only the relevant subset of its DNA, producing the specific proteins that give it its specialised structure and function.

5. Comparing Totipotent and Pluripotent Cells

Examiners frequently ask you to compare these two cell types. The table below consolidates the key distinctions — learn these precisely, because a vague answer that conflates the two will not score full marks.

6. Evaluating the Use of Stem Cells in Treating Human Disorders

The specification requires you to evaluate the use of stem cells in treating human disorders — not merely describe it. Evaluation means weighing evidence on both sides and reaching a reasoned conclusion. Here is how to build that argument systematically.

Pluripotent stem cells hold genuine therapeutic promise because they can, in principle, be directed to differentiate into any cell type needed to replace damaged or diseased tissue. Conditions where this is being actively investigated include Parkinson's disease (replacement of dopaminergic neurons), type 1 diabetes (replacement of insulin-secreting beta cells), spinal cord injury, and certain forms of blindness involving retinal degeneration.

A significant development has been the production of induced pluripotent stem cells (iPSCs). These are adult somatic cells — for example, skin fibroblasts — that have been reprogrammed back to a pluripotent state by introducing specific transcription factor genes. iPSCs sidestep the ethical objections associated with embryo destruction, and because they can be derived from the patient's own cells, they reduce the risk of immune rejection.

• Potential to replace any damaged cell type, offering treatments for currently incurable conditions
• Pluripotent cells can divide in unlimited numbers, providing a scalable cell source
• iPSCs can be patient-matched, reducing immune rejection risk
• Research using stem cells has advanced understanding of developmental biology and drug testing

Against these benefits, there are substantial concerns. Embryonic stem cell (ESC) research requires the destruction of human embryos at the blastocyst stage, which raises serious ethical objections for those who regard the embryo as having full moral status from fertilisation. There is also the risk that transplanted stem cells may not differentiate correctly in vivo, or may proliferate uncontrollably — potentially forming tumours called teratomas.

• Harvesting ESCs destroys the embryo — ethically contested
• Risk of uncontrolled proliferation leading to tumour (teratoma) formation
• iPSC reprogramming can introduce mutations; long-term safety not yet fully established
• Immune rejection remains a risk when donor-derived cells are used
• Many therapies are still experimental; clinical evidence of efficacy is limited for most conditions

A balanced evaluation must acknowledge that the ethical weight of objections depends on one's view of embryo moral status — a philosophical question without a single scientific answer. From a purely scientific standpoint, iPSCs represent a promising route that avoids embryo destruction, but technical challenges around reprogramming fidelity and long-term safety remain active areas of research.

7. Exam Technique: Scoring Full Marks on Stem Cell Questions

AQA questions on this topic tend to fall into three categories: definition/description questions, mechanistic explanation questions, and extended evaluate questions. Each demands a different approach.

For definition questions, precision is everything. Do not write "totipotent cells can become any cell" — write "totipotent cells can divide and produce any type of body cell, including extraembryonic tissues." The inclusion of extraembryonic tissues is the mark-winning detail that separates a totipotent cell from a pluripotent one.

For mechanistic explanation questions asking how specialisation occurs, always link the mechanism to the outcome: state that only part of the DNA is translated (transcribed and then translated), and that this results in only certain proteins being produced, giving the cell its specific structure and function. A chain of cause and effect scores more marks than a list of facts.